PL-6983
| Clinical data | |
|---|---|
| Routes of administration |
Subcutaneous injection |
| Identifiers | |
| CAS Number | |
PL-6983 is a synthetic peptide and selective MC4 receptor agonist which is under development by Palatin Technologies for the treatment of female sexual dysfunction and erectile dysfunction. It was developed as a successor to/replacement of bremelanotide (PT-141) due to concerns of the side effect of increased blood pressure seen with the latter in clinical trials. Relative to bremelanotide, PL-6983 produces significantly lower increases in blood pressure in animal models. The drug has reportedly been in pre-clinical development for all medical indications since 2008. Palatin has stated that "We are focusing development efforts on bremelanotide for [female sexual dysfunction], but are continuing evaluation of PL-6983." The chemical structure of PL-6983 has yet to be made public.
See also
External links
- PL-6983 for Sexual Dysfunction - Palatin Technologies
- PL-6983 for Female Sexual Dysfunction - Palatin Technologies
- Palatin Obtains $21.1M to Advance Programs in Female Sexual Dysfunction and Asthma - Genetic Engineering and Biotechnology News
- Research Programme: Sexual Dysfunction Therapy (PL-6983) - Palatin Technologies - AdisInsight
- How Sildenax Works? Composition & Benefits of Sildenax - Nutri Medi
- How Medicines Work To Improve Potency - Vera Farmacia
| MC1 |
|
|---|---|
| MC2 | |
| MC3 | |
| MC4 |
|
| MC5 |
|
| Unsorted | |
| Others |
|